Zou Xueqing, Wang Yongmei, Luan Mingyuan, Zhang Yizheng
Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.
Front Pharmacol. 2025 May 22;16:1605162. doi: 10.3389/fphar.2025.1605162. eCollection 2025.
Hepatocellular carcinoma is a highly aggressive and heterogeneous malignancy with limited understanding of its heterogeneity.
In this study, we applied ten multi-omics classification algorithms to identify three distinct molecular subtypes of HCC (C1-C3). To further explore the immune microenvironment of these molecular subtypes, we leveraged single-cell transcriptomic data and employed CIBERSORTx to deconvolute their immune landscape.
Among them, C3 exhibited the worst prognosis, whereas C1 and C2 were associated with relatively better clinical outcomes. Patients in the C3 group exhibited a high burden of copy number variations, mutation load, and methylation silencing. Our results revealed that compared to C1 and C2, C3 had a lower proportion of hepatocytes but a higher proportion of cholangiocytes and macrophages. Through analyses of hepatocyte, cholangiocyte, and macrophage subpopulations, we characterized their functional states, spatial distribution preferences, evolutionary relationships, and transcriptional regulatory networks, ultimately identifying cell subpopulations significantly associated with patient survival. Furthermore, we identified key ligand-receptor interactions, such as APOA1-TREM2 and APOA2-TREM2 in hepatocyte-macrophage crosstalk, and VTN-PLAUR in cholangiocyte-macrophage communication.
Finally, we employed machine learning methods to construct a prognostic model for HCC patients and identified novel potential compounds for high risk patients. In summary, our novel multi-omics classification of HCC provides valuable insights into tumor heterogeneity and prognosis, offering potential clinical applications for precision oncology.
肝细胞癌是一种侵袭性很强且具有异质性的恶性肿瘤,人们对其异质性的了解有限。
在本研究中,我们应用了十种多组学分类算法来识别肝细胞癌的三种不同分子亚型(C1 - C3)。为了进一步探索这些分子亚型的免疫微环境,我们利用单细胞转录组数据并采用CIBERSORTx对其免疫格局进行解卷积分析。
其中,C3表现出最差的预后,而C1和C2与相对较好的临床结果相关。C3组患者的拷贝数变异、突变负荷和甲基化沉默负担较高。我们的结果显示,与C1和C2相比,C3的肝细胞比例较低,但胆管细胞和巨噬细胞比例较高。通过对肝细胞、胆管细胞和巨噬细胞亚群的分析,我们表征了它们的功能状态、空间分布偏好、进化关系和转录调控网络,最终确定了与患者生存显著相关的细胞亚群。此外,我们还确定了关键的配体 - 受体相互作用,例如肝细胞 - 巨噬细胞相互作用中的APOA1 - TREM2和APOA2 - TREM2,以及胆管细胞 - 巨噬细胞通讯中的VTN - PLAUR。
最后,我们采用机器学习方法构建了肝细胞癌患者的预后模型,并为高危患者确定了新的潜在化合物。总之,我们对肝细胞癌进行的新型多组学分类为肿瘤异质性和预后提供了有价值的见解,为精准肿瘤学提供了潜在的临床应用。